Skip to main content

Table 2 Efficacy parameters for prediction of clinical diagnosis 1 year post scan: modified H&Y stage ( n = 92)

From: Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCANTM) in subjects with clinically uncertain parkinsonian syndromes

Subjects with CUPS

Clinical diagnosis at 1 year post-scan

Subgroup: modified H&Y stage <2

Subgroup: modified H&Y stage ≥2

PS

Non-PS

Total

PS

Non-PS

Total

Abnormal ioflupane [ 123 I] images a

26

0

26

20

2

22

Normal ioflupane [ 123 I] images

2

20

22

1

21

22

Total

28

20

48

21

23

44

Statistic

Result

Exact 95% CI

 

Result

Exact 95% CI

P value/analysis method b

Sensitivity c

0.9286

(0.7650, 0.9912)

 

0.9524

(0.7618, 0.9988)

1.0000

Specificity d

1.0000

(0.8316, 1.0000)

 

0.9130

(0.7196, 0.9893)

0.4906

Accuracy

0.9583

(0.8575, 0.9949)

 

0.9318

(0.8134, 0.9857)

0.6673

Positive predictive value

1.0000

(0.8677, 1.0000)

 

0.9091

(0.7084, 0.9888)

0.2048

Negative predictive value

0.9091

(0.7084, 0.9888)

 

0.9545

(0.7716, 0.9988)

1.0000

  1. CI, confidence interval; CUPS, clinically uncertain parkinsonian syndrome; H&Y, Hoehn and Yahr; PS: parkinsonian syndrome. aAbnormal imaging types 1, 2 and 3. b P value is based on Fisher’s exact test. cSensitivity is equivalent to positive percent agreement. dSpecificity is equivalent to negative percent agreement.